Literature DB >> 10747691

Practice guidelines for the diagnosis and treatment of Alzheimer's disease in a managed care setting: Part II--Pharmacologic therapy. Alzheimer's Disease (AD) Managed Care Advisory Council.

H Fillit1, J Cummings.   

Abstract

The progressive loss of social and physical functioning associated with Alzheimer's disease (AD) results in extensive social and economic costs to society. The early diagnosis and treatment of AD may reduce cognitive and behavioral symptoms of this disease and may slow disease progression, thereby alleviating some of these social and economic costs. The Alzheimer's Disease Managed Care Advisory Council, a panel of experts from managed care, academic medicine, and the Los Angeles chapter of the Alzheimer's Association was convened to synthesize current evidence-based recommendations for AD diagnostic and treatment guidelines and to integrate these guidelines for use in MCOs. This paper presents conclusions from this panel and provides an algorithm for the treatment of AD specifically for managed care settings. When combined with other necessary efforts to educate providers, these guidelines should improve the cost-effectiveness and quality of care for individuals with dementia in managed care.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10747691

Source DB:  PubMed          Journal:  Manag Care Interface        ISSN: 1096-5645


  9 in total

1.  Effectiveness of a specific care plan in patients with Alzheimer's disease: cluster randomised trial (PLASA study).

Authors:  Fati Nourhashemi; Sandrine Andrieu; Sophie Gillette-Guyonnet; Bruno Giraudeau; Christelle Cantet; Nicola Coley; Bruno Vellas
Journal:  BMJ       Date:  2010-06-03

Review 2.  Rivastigmine transdermal patch: in the treatment of dementia of the Alzheimer's type.

Authors:  Lily P H Yang; Gillian M Keating
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

3.  A randomized trial of the impact of a specific care plan in 1120 Alzheimer's patients (PLASA Study) over a two-year period: design and baseline data.

Authors:  F Nourhashemi; S Gillette-Guyonnet; S Andrieu; Y Rolland; P-J Ousset; B Vellas
Journal:  J Nutr Health Aging       Date:  2008-04       Impact factor: 4.075

4.  Behavioural symptoms in patients with Alzheimer's disease and their association with cognitive impairment.

Authors:  Manuel Fernández; Ana L Gobartt; Montse Balañá
Journal:  BMC Neurol       Date:  2010-09-28       Impact factor: 2.474

5.  Physiologic modulation of natural killer cell activity as an index of Alzheimer's disease progression.

Authors:  Paolo Prolo; Francesco Chiappelli; Alberto Angeli; Andrea Dovio; Paola Perotti; Marisa Pautasso; Maria Luisa Sartori; Laura Saba; Stefano Mussino; Thomas Fraccalini; Fausto Fantó; Cristina Mocellini; Maria Gabriella Rosso; Enzo Grasso
Journal:  Bioinformation       Date:  2007-03-21

6.  Evidence-Based Research in Complementary and Alternative Medicine III: Treatment of Patients with Alzheimer's Disease.

Authors:  Francesco Chiappelli; Audrey M Navarro; David R Moradi; Ercolano Manfrini; Paolo Prolo
Journal:  Evid Based Complement Alternat Med       Date:  2006-11-10       Impact factor: 2.629

7.  Comparison of persistence rates of acetylcholine-esterase inhibitors in a state Medicaid program.

Authors:  Susan M Abughosh; Stephen J Kogut
Journal:  Patient Prefer Adherence       Date:  2008-02-02       Impact factor: 2.711

8.  Neuroendocrine immunity in patients with Alzheimer's disease: toward translational epigenetics.

Authors:  Francesco Chiappelli; Paolo Prolo; Kristine D Cajulis; Alberto Angeli; Andrea Dovio; Paola Perotti; Marisa Pautasso; Maria Luisa Sartori; Laura Saba; Stefano Mussino; Thomas Fraccalini; Fausto Fanto; Ercolano Manfrini; Cristina Mocellini; Maria Gabriella Rosso; Enzo Grasso
Journal:  Bioinformation       Date:  2007-05-20

9.  Association Between Hormone-Modulating Breast Cancer Therapies and Incidence of Neurodegenerative Outcomes for Women With Breast Cancer.

Authors:  Gregory L Branigan; Maira Soto; Leigh Neumayer; Kathleen Rodgers; Roberta Diaz Brinton
Journal:  JAMA Netw Open       Date:  2020-03-02
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.